SEARCH

SEARCH BY CITATION

References

  • 1
    Hamano T, Matsui H, Sekine Y, Ohtake N, Nakata S, Suzuki K. Association of SNP rs1447295 and microsatellite marker DG8S737 with familial prostate cancer and high grade disease. J Urol 2010; 184: 738742.
  • 2
    Center MM, Jemal A, Lortet-Tieulent J Ward E, Ferlay J, Brawley O, Bray F. International variation in prostate cancer incidence and mortality rates. Eur Urol. 2012; 61: 10791092.
  • 3
    Hällström TM, Laiho M. Genetic changes and DNA damage responses in the prostate. Prostate 2008; 68: 902918.
  • 4
    Bostwick DG, Burke HB, Djakiew D, Euling S, Ho SM, Landolph J, Morrison H, Sonawane B, Shifflett T, Waters DJ, et al. Human prostate cancer risk factors. Cancer 2004; 101(10 Suppl): 23712490.
  • 5
    Vrdoljak E, Wojtukiewicz MZ, Pienkowski T, Bodoky G, Berzinec P, Finek J, Todorović V, Borojević N, Croitoru A; South Eastern European Research Oncology Group. Cancer epidemiology in central, south and eastern European countries. Croat Med J. 2011; 52: 478487.
  • 6
    Cancer Registry of Central Serbia. Institute of Public Health of the Republic of Serbia 1999–2009. Available at: http://www.batut.org.rs/. Accessed March 2, 2012.
  • 7
    Gudmundsson J, Sulem P, Steinthorsdottir V, Bergthorsson JT, Thorleifsson G, Manolescu A, Rafnar T, Gudbjartsson D, Agnarsson BA, Baker A, et al. Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet. 2007; 39(8): 977983.
  • 8
    Bach I, Mattei MG, Cereghini S, Yaniv M. Two members of an HNF1 homeoprotein family are expressed in human liver. Nucleic Acids Res. 1991; 19: 35533559.
  • 9
    Horikawa Y, Iwasaki N, Hara M, Furuta H, Hinokio Y, Cockburn BN, Lindner T, Yamagata K, Ogata M, Tomonaga O, et al. Mutation in hepatocyte nuclear factor-1 beta gene (TCF2) associated with MODY. Nat Genet. 1997; 17: 384385.
  • 10
    Bingham C, Ellard S, Allen L, Bulman M, Shepherd M, Frayling T, Berry PJ, Clark PM, Lindner T, Bell GI, et al. Abnormal nephron development associated with a frameshift mutation in the transcription factor hepatocyte nuclear factor-1 beta. Kidney Int. 2000; 57: 898907.
  • 11
    Maestro MA, Boj SF, Luco RF, Pierreux CE, Cabedo J, Servitja JM, German MS, Rousseau GG, Lemaigre FP, Ferrer J. Hnf6 and Tcf2 (MODY5) are linked in a gene network operating in a precursor cell domain of the embryonic pancreas. Hum Mol Genet. 2003; 12: 33073314.
  • 12
    Zheng SL, Sun J, Wiklund F, Smith S, Stattin P, Li G, Adami HO, Hsu FC, Zhu Y, Bälter K, et al. Cumulative association of five genetic variants with prostate cancer. N Engl J Med. 2008; 358: 910919.
  • 13
    Levin AM, Machiela MJ, Zuhlke KA, Ray AM, Cooney KA, Douglas JA. Chromosome 17q12 variants contribute to risk of early-onset prostate cancer. Cancer Res. 2008; 68(16): 64926495.
  • 14
    Sun J, Purcell L, Gao Z, Isaacs SD, Wiley KE, Hsu FC, Liu W, Duggan D, Carpten JD, Grönberg H, et al. Association between sequence variants at 17q12 and 17q24.3 and prostate cancer risk in European and African Americans. Prostate 2008; 68(7): 691697.
  • 15
    Stevens VL, Ahn J, Sun J, Jacobs EJ, Moore SC, Patel AV, Berndt SI, Albanes D, Hayes RB. HNF1B and JAZF1 genes, diabetes, and prostate cancer risk. Prostate 2010; 70(6): 601607.
  • 16
    Berndt SI, Sampson J, Yeager M, Jacobs KB, Wang Z, Hutchinson A, Chung C, Orr N, Wacholder S, Chatterjee N, et al. Large-scale fine mapping of the HNF1B locus and prostate cancer risk. Hum Mol Genet. 2011; 20(16): 33223329.
  • 17
    Kim HJ, Bae JS, Lee J, Chang IH, Kim KD, Shin HD, Han JH, Lee SY, Kim W, Myung SC. HNF1B polymorphism associated with development of prostate cancer in Korean patients. Urology 2011; 78(4): 969.e1969.e6.
  • 18
    Chang BL, Spangler E, Gallagher S, Haiman CA, Henderson B, Isaacs W, Benford ML, Kidd LR, Cooney K, Strom S, et al. Validation of genome-wide prostate cancer associations in men of African descent. Cancer Epidemiol Biomarkers Prev. 2011; 20(1): 2332.
  • 19
    Haiman CA, Chen GK, Blot WJ, Strom SS, Berndt SI, Kittles RA, Rybicki BA, Isaacs WB, Ingles SA, Stanford JL, et al. Genome-wide association study of prostate cancer in men of African ancestry identifies a susceptibility locus at 17q21. Nat Genet. 2011; 43(6): 570573.
  • 20
    Hooker S, Hernandez W, Chen H, Robbins C, Torres JB, Ahaghotu C, Carpten J, Kittles RA. Replication of prostate cancer risk loci on 8q24, 11q13, 17q12, 19q33, and Xp11 in African Americans. Prostate 2010; 70(3): 270275.
  • 21
    Gallagher DJ, Vijai J, Cronin AM, Bhatia J, Vickers AJ, Gaudet MM, Fine S, Reuter V, Scher HI, Halldén C, et al. Susceptibility loci associated with prostate cancer progression and mortality. Clin Cancer Res. 2010; 16(10): 28192832.
  • 22
    Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol. 1974; 111: 5864.
  • 23
    Catalona WJ, Hudson MA, Scardino PT, Richie JP, Ahmann FR, Flanigan RC, deKernion JB, Ratliff TL, Kavoussi LR, Dalkin BL, et al. Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves. J Urol. 1994; 152: 20372042.
  • 24
    D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998; 280: 969974.
  • 25
    Medeiros RM, Morais A, Vasconcelos A, Costa S, Pinto D, Oliveira J, Ferreira P, Lopes C. Outcome in prostate cancer: association with endothelial nitric oxide synthase Glu-Asp298 polymorphism at exon 7. Clin Cancer Res. 2002; 8: 34333437.
  • 26
    Solé X, Guinó E, Valls J, Iniesta R, Moreno V. SNPStats: a web tool for the analysis of association studies. Bioinformatics 2006; 22(15): 19281929.
  • 27
    Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, deBakker PI, Daly MJ, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007; 81(3): 559575.
  • 28
    Wallace BC, Dahabreh IJ, Trikalinos TA, Lau J, Trow P, Schmid CH. Closing the gap between methodologists and end-users: R as a computational back-end. J Stat Softw. 2012; 49(5): 115. Available at: http://www.jstatsoft.org/v49/i05/paper.
  • 29
    Der Simonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177188.
  • 30
    Eeles RA, Kote-Jarai Z Giles GG, Olama AA, Guy M, Jugurnauth SK, Mulholland S, Leongamornlert DA, Edwards SM, Morrison J, et al. Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet. 2008; 40(3): 316321.